Veloce BioPharma LLC
USPTO PatentsView assignee record - 6 granted patents across 2 technology areas, recorded in grant years 2016–2019. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).
The verdict
According to USPTO PatentsView, Veloce ranks #43,914 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 2 technology areas.
- #43,914
- of 49,997 US assignees by volume
- 8th percentile
- by Innovation Score (21.2/100)
- 15.8
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R43914 · US Corporation #43,914 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #43,914/49,997
- PHOTO-FINISH Vaztec
- CPC-NARROW A61K · 2 areas
- INNOV-THIN 21.2/100
- CLAIMS-RICH 15.8 claims/avg
- TYPE-USCORP US Corporation
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Vaztec, LLC (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Veloce’s 21.2 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Veloce
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Veloce BioPharma · this assignee 21
Veloce BioPharma · this assignee
21 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Veloce's Innovation Score is 21.2/100 (8th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Veloce?
Each dot is one of Veloce’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Veloce’s own 15.8 claims/patent is ABOVE the 13.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Veloce's grants concentrate
Veloce BioPharma LLC is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2016. By volume, Veloce sits between Vaztec, LLC and Venn Technology Corporation.
Who files at Veloce's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Vaztec
Vaztec, LLC
6 patents
- Vechain Global Te…
VeChain Global Technology, S.AR.L
6 patents
- Veebot Systems
Veebot Systems, Inc.
6 patents
- Veil Intimates
Veil Intimates LLC
6 patents
- Velocity Systems
Velocity Systems LLC
6 patents
- Vengo
Vengo Inc.
6 patents
- Venn Biosciences
Venn Biosciences Corporation
6 patents
- Venn Technology
Venn Technology Corporation
6 patents
- Veloce Biopharma ◀
Veloce BioPharma LLC
6 patents
What this shows Veloce holds 6 patents at rank #43,934, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Veloce
By rank, the assignees closest to #43,934 in granted patent volume.
- Vaztec, LLC #43,930 · 6 patents
- VeChain Global Technology, S.AR.L #43,931 · 6 patents
- Veebot Systems, Inc. #43,932 · 6 patents
- Veil Intimates LLC #43,933 · 6 patents
- Velocity Systems LLC #43,935 · 6 patents
- Vengo Inc. #43,936 · 6 patents
- Venn Biosciences Corporation #43,937 · 6 patents
- Venn Technology Corporation #43,938 · 6 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Veloce's primary technology class.
- The Regents of the University of California 1,779 in class
- L'Oreal 1,250 in class
- Novartis AG 988 in class
- The Procter & Gamble Company 985 in class
- The Board of Regents of the University of Texas System 950 in class
- The United States of America, as represented by the Secretary, Department of Health and Human Services 813 in class
- The Trustees of the University of Pennsylvania 768 in class
- Merck Sharp & Dohme LLC 760 in class
Veloce's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
21 8th percentile higher than 8% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 16.7% |
| 2017 | 2 | 33.3% |
| 2019 | 3 | 50.0% |
Which technologies does Veloce BioPharma LLC patent most?
Top 2 of 2 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Veloce BioPharma LLC's patent record in context - here's where to go next.
- Veloce BioPharma LLC's lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
- Ranked #43,914 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Veloce BioPharma LLC against Vaztec, LLC, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 21.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.